Hydrobromides
Medchemexpress LLC Burixafor (hydrobromide) | 1191450-19-7 | 98.0% | 769.01 | 1 ML
Burixafor hydrobromide is a potent CXCR4 antagonist that inhibits the binding of CXCL12 to CXCR4 and blocks downstream signaling. It mobilizes CD34+ hematopoietic stem/progenitor cells from bone marrow to peripheral blood. This compound is used for research on autologous hematopoietic stem cell transplantation (ASCT).
- Potent CXCR4 antagonist with a pIC50 of 7.4.
- Inhibits binding of CXCL12 to CXCR4.
- Mobilizes CD34+ hematopoietic stem/progenitor cells.
- Useful for research on autologous hematopoietic stem cell transplantation.
Medchemexpress LLC CPTH6 hydrobromide 1mg | 2321332-57-2 | 1 MG
CPTH6 hydrobromide is a thiazole-derived small molecule that modulates histone acetyltransferase activity and induces apoptotic and autophagic features in leukemia cell lines. It is provided as the hydrobromide salt for use in biochemical and cell-based cancer research applications.
- Thiazole-derived HAT inhibitor that reduces histone acetylation.
- Promotes apoptotic program and increases autophagic features in leukemia cells.
- Provided as a solid hydrobromide salt for improved handling and stability.
- Suitable for biochemical assays and cell-based studies of acetylation-dependent processes.
- Supplied in small research quantities for screening and mechanistic experiments.
Medchemexpress LLC Burixafor (hydrobromide) | 1191450-19-7 | 98.0% | 769.01 | 50 MG
Burixafor hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4. It inhibits CXCL12 binding to CXCR4, antagonizes Gαᵢ and β-arrestin2 recruitment, and blocks downstream Gαᵢ-mediated effects on cAMP signal transduction. This compound mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC) for research on autologous hematopoietic stem cell transplantation (ASCT).
- Potent CXCR4 antagonist with a pIC50 of 7.4.
- Inhibits CXCL12 binding to CXCR4.
- Antagonizes CXCL12-induced Gαᵢ and β-arrestin2 recruitment.
- Blocks downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction.
- Mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC).
- Useful for research on autologous hematopoietic stem cell transplantation (ASCT).
Medchemexpress LLC Remodelin hydrobromide | 1622921-15-6 | 99.6% | 363.28 | 100 MG
Remodelin hydrobromide is an orally active and selective inhibitor of acetyltransferase NAT10. It inhibits NAT10 activity, slows DNA replication, and suppresses the growth of prostate cancer cells. It has been shown to inhibit the growth of prostate cancer and hepatocellular carcinoma in xenograft models. Additionally, Remodelin hydrobromide enhances the healthspan in the Hutchinson-Gilford progeria syndrome (HGPS) mouse model.
- Inhibits NAT10 activity and cell proliferation in prostate cancer cells.
- Slows DNA replication.
- Suppresses the growth of prostate cancer cells.
- Inhibits the growth of hepatocellular carcinoma in xenograft models.
- Enhances healthspan in the HGPS mouse model.
- Decreases nuclear shape defects and increases genomic stability in fibroblasts.
Medchemexpress LLC Burixafor hydrobromide | 1191450-19-7 | 98.0% | 769.01 | 200 MG
Burixafor (TG-0054) hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4. It inhibits the binding of CXCL12 to CXCR4, antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2, and blocks the downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction. It mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC) from the bone marrow to the peripheral blood and can be used for research on autologous hematopoietic stem cell transplantation (ASCT).
- Potent CXCR4 antagonist (pIC50 of 7.4)
- Inhibits CXCL12 binding to CXCR4
- Antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2
- Blocks downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction
- Mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC) from bone marrow to peripheral blood
- Potential for research on autologous hematopoietic stem cell transplantation (ASCT)
Apexbio Technology LLC Teneligliptin hydrobromide 906093-29-6 10mM (in 1mL DMSO)
Teneligliptin hydrobromide (CAS 906093-29-6) is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor exhibiting competitive inhibition of human and rat plasma DPP-4 with an IC50 of approximately 1 nM DPP-4 also known as CD26 is a cell surface protease involved in immunoregulation signal transduction and apoptosis In vitro Teneligliptin hydrobromide reduces reactive oxygen species and modulates cell cycle and apoptotic gene expression in human endothelial cells exposed to high glucose In vivo it ameliorates hepatic steatosis and metabolic disturbances in murine models partly through activation of hepatic AMPK This compound supports studies of metabolic oxidative and inflammatory pathways
Medchemexpress LLC Burixafor hydrobromide | 1191450-19-7 | 98.0% | 769.01 | 100 MG
Burixafor (TG-0054) hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4. It inhibits the binding of CXCL12 to CXCR4, antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2, and blocks the downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction. Burixafor hydrobromide mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC) from the bone marrow to the peripheral blood and can be used for research on autologous hematopoietic stem cell transplantation (ASCT).
- Potent CXCR4 antagonist with a pIC50 of 7.4
- Inhibits CXCL12 binding to CXCR4
- Antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2
- Blocks downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction
- Mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC) from bone marrow to peripheral blood
- Can be used for research on autologous hematopoietic stem cell transplantation (ASCT)
Medchemexpress LLC BC-11 hydrobromide | 443776-49-6 | 99.0% | 290.97 | 25 MG
BC-11 hydrobromide is a selective TMPRSS2 inhibitor and a selective urokinase (uPA) inhibitor. It demonstrates cytotoxicity against triple-negative MDA-MB231 breast cancer cells.
- Selective TMPRSS2 inhibitor
- Selective urokinase (uPA) inhibitor
- Cytotoxic to triple-negative MDA-MB231 breast cancer cells
- Used in research on viral infections and cancer
Medchemexpress LLC Burixafor hydrobromide | 1191450-19-7 | 98.0% | 769.01 | 500 MG
Burixafor (TG-0054) hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4. It inhibits the binding of CXCL12 to CXCR4, antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2, and blocks the downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction. Burixafor hydrobromide mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC) from the bone marrow to the peripheral blood.
- Can be used for research on autologous hematopoietic stem cell transplantation (ASCT).
- Potent CXCR4 antagonist.
- Inhibits CXCL12 binding to CXCR4.
- Blocks Gαᵢ-mediated inhibitory effect on cAMP signal transduction.
- Mobilizes CD34+ hematopoietic stem/progenitor cells.
Apexbio Technology LLC Homatropine Bromide 51-56-9 10mM (in 1mL DMSO)
Homatropine Bromide (CAS 51-56-9) is a small molecule antagonist of muscarinic acetylcholine receptors (AChRs) It selectively inhibits muscarinic receptor-mediated responses in endothelial and smooth muscle cells with reported IC50 values of 162 5 nM and 170 3 nM for WKY-E and SHR-E cell models respectively This compound serves as a valuable tool for investigating the role of muscarinic signaling in vascular function and smooth muscle physiology within experimental research settings
Medchemexpress LLC Vortioxetine hydrobromide | 960203-27-4 | C18H23BrN2S | 5 MG
Vortioxetine hydrobromide is a multimodal serotonergic agent that acts as an antagonist of 5-HT3A and 5-HT7 receptors and an inhibitor of 5-hydroxytryptamine transporter (SERT). It also functions as a 5-HT1A agonist and a partial 5-HT1B agonist. This product is intended for research use only and has not been fully validated for medical applications.
- Antagonist of 5-HT3A and 5-HT7 receptors
- Inhibitor of 5-hydroxytryptamine transporter (SERT)
- 5-HT1A agonist and partial 5-HT1B agonist
- Multimodal serotonergic agent
- Increases cell proliferation and cell survival
- Stimulates maturation of immature granule cells
- Does not cause cognitive or psychomotor impairment
Medchemexpress LLC Darifenacin hydrobromide | 133099-07-7 | 99.8% | C28H31BrN2O2 | 5 MG
Darifenacin hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist. It is used in the study of urinary incontinence and other symptoms of overactive bladder, and has demonstrated anti-tumor effects by inhibiting tumor growth in colorectal cancer cells. In vitro, it inhibits Kv currents and the phosphorylation of p38, ERK1/2, and Akt. In vivo studies showed antitumor effects in xenograft mouse models and decreased afferent activity in rat bladders.
- Selective and orally active M3 muscarinic receptor antagonist
- Used in the study of urinary incontinence and overactive bladder symptoms
- Exhibits anti-tumor effects in colorectal cancer cells
- Inhibits Kv currents in coronary arterial smooth muscle cells
- Decreases afferent activity of bladder Aδ and C fibers in female rats
Apexbio Technology LLC Homatropine Bromide 51-56-9 5g
Homatropine Bromide (CAS 51-56-9) is a small molecule antagonist of muscarinic acetylcholine receptors (AChRs) It selectively inhibits muscarinic receptor-mediated responses in endothelial and smooth muscle cells with reported IC50 values of 162 5 nM and 170 3 nM for WKY-E and SHR-E cell models respectively This compound serves as a valuable tool for investigating the role of muscarinic signaling in vascular function and smooth muscle physiology within experimental research settings
Apexbio Technology LLC Homatropine Bromide 51-56-9 1g
Homatropine Bromide (CAS 51-56-9) is a small molecule antagonist of muscarinic acetylcholine receptors (AChRs) It selectively inhibits muscarinic receptor-mediated responses in endothelial and smooth muscle cells with reported IC50 values of 162 5 nM and 170 3 nM for WKY-E and SHR-E cell models respectively This compound serves as a valuable tool for investigating the role of muscarinic signaling in vascular function and smooth muscle physiology within experimental research settings
Medchemexpress LLC Darifenacin (hydrobromide) | 133099-07-7 | 99.38% | C28H31BrN2O2 | 1 ML
Darifenacin hydrobromide, a selective M3 muscarinic receptor (M3R) antagonist, is provided as a 10 mM solution in 1 mL of DMSO. It is used in studies of urinary incontinence and overactive bladder symptoms. Research also highlights its ability to inhibit tumor growth in colorectal cancer cells, demonstrating anti-tumor effects.
- Selective M3 muscarinic receptor antagonist
- Potential for urinary incontinence and overactive bladder research
- Inhibits tumor growth in colorectal cancer cells
- Supplied as a 10 mM solution in 1 mL DMSO